title: Miniaturized self-expanding drug-eluting stent in small coronary arteries: late effectiveness.
abstract: BACKGROUND
  Small vessels represent a risk factor for restenosis in percutaneous coronary angioplasty (PCA). The Sparrow® self-expanding drug-eluting stent, which has a lower profile than the current systems, has never been tested in this scenario.
  
  
  OBJECTIVE
  To evaluate the late effectiveness of the Sparrow® drug-eluting stent, regarding in-stent late lumen loss (LLL).
  
  
  METHODS
  Patients with ischemia, symptomatic or documented, were submitted to PCA in vessels with reference diameter < 2.75 mm, divided into two groups regarding Sparrow® stent type: group 1: Sparrow® drug-eluting stent (DES), group 2: Sparrow® bare metal stent (BMS). Clinical follow-up duration was 12 months. Evaluation using quantitative coronary angiography (QCA) was performed immediately and at 8 months. A decrease of over 65% of in-stent LLL with DES was estimated to calculate sample size. IBM® SPSS software, release 19 (Chicago, Illinois, USA) was used for the statistical analysis.
  
  
  RESULTS
  A total of 24 patients were randomized, 12 in each group. The DES and BMS groups were similar in age (63.25 ± 10.01 vs. 64.58 ± 11.54, p = 0.765), male gender (58.3% vs. 33.3%, p = 0.412), risk factors and all angiographs aspects. Immediate results were satisfactory in both groups. At 8 months in-stent late lumen loss was significantly lower in DES than in BMS group (DES vs. BMS 0.25 ± 0.16 0.97 ± 0.76, p = 0.008).
  
  
  CONCLUSIONS
  In small-vessel PCA, the Sparrow® DES determined significant reduction in in-stent LLL, when compared to Sparrow® BMS.
authors.forename: Flavio Roberto Azevedo de
authors.initials: FR
authors.lastname: Oliveira
authors.forename: Luiz Alberto Piva E
authors.initials: LA
authors.lastname: Mattos
authors.forename: Alexandre
authors.initials: A
authors.lastname: Abizaid
authors.forename: Andrea S
authors.initials: AS
authors.lastname: Abizaid
authors.forename: J Ribamar
authors.initials: JR
authors.lastname: Costa
authors.forename: Ricardo
authors.initials: R
authors.lastname: Costa
authors.forename: Rodolfo
authors.initials: R
authors.lastname: Staico
authors.forename: Roberto
authors.initials: R
authors.lastname: Botelho
authors.forename: J Eduardo
authors.initials: JE
authors.lastname: Sousa
authors.forename: Amanda
authors.initials: A
authors.lastname: Sousa
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D023903:Coronary Restenosis / Q000517:prevention & control*; D023921:Coronary Stenosis; D003331:Coronary Vessels / Q000503:physiopathology*; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008904:Miniaturization; D020123:Sirolimus / Q000008:administration & dosage; D015607:Stents; D016896:Treatment Outcome
chemical_list: D020123:Sirolimus